Tempus AI stock fell Monday after the medical artificial intelligence company reported fourth-quarter results.
Tempus AI (TEM) reported a loss of 18 cents a share on revenue of $200.7 million. The company said it expects full year 2025 revenue of roughly $1.24 billion for its consolidated Tempus and Ambry Genetics business.
↑ X NOW PLAYING Indexes Down But Stocks Mixed; Progressive, Dutch Bros, Palantir In FocusChief Executive Eric Lefkofsky said the company's "investments in AI have positioned us well for the future."
But Tempus AI stock fell more than 8% to 63.72 in extended trading. The stock gained 2.2% to close at 69.57 in regular trading.
The shares have Relative Strength Rating of 93, according to IBD MarketSurge.
YOU MAY ALSO LIKE:
IBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat Earnings
Alibaba Stock Falls After China Tech Giant Pledges $52 Billion AI Spending Push
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.